Berberine and Polycystic Ovary Syndrome
Primary Purpose
Polycystic Ovary Syndrome, Berberine
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Berberine
Sponsored by
About this trial
This is an interventional treatment trial for Polycystic Ovary Syndrome focused on measuring berberine, Polycystic Ovary Syndrome
Eligibility Criteria
Inclusion Criteria:
- normal and overweight women (Body Mass Index (BMI) 25-30 kg/m2)
- newly detected Polycystic Ovary Syndrome
Exclusion Criteria:
- any concomitant medication
- presence of liver, renal and thyroid disease
- smoking
- drinking more than two standard alcoholic beverages/day (20 g of alcohol/day)
Sites / Locations
- Azienda di Servizi alla Persona
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Berberine
Arm Description
2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
Outcomes
Primary Outcome Measures
Changes on insulin resistance
Homeostasis Model Assessment (pt), for evaluate insulin resistance if > 2.4
Secondary Outcome Measures
Changes on inflammation
C-Reactive Protein (mg/dl)
Changes on inflammation
Tumor Necrosis Factor alpha (pg/ml)
Changes on lipid profile
Total Cholesterol (mg/dl), High Density Lipoprotein Cholesterol (mg/dl), Low Density Lipoprotein Cholesterol (mg/dl), Very Low Density Lipoprotein (mg/dl),Triglycerides (mg/dl)
Changes on Carbohydrate profile
Glycemia (mg/dl)
Changes on Carbohydrate profile
Insulin (mcU/ml)
Changes on Hormonal profile
Sex Hormone Binding Globulin (nmol/l)
Changes on Hormonal profile
Testosterone (ng/ml)
Changes on Hormonal profile
Free Androgen Index (ratio)
Changes on safety
Aspartate aminotransferase (IU/l), alanine aminotransferase (IU/l)
Changes on safety
Total bilirubin (mg/dl)
Changes on safety
Gamma Glutamyl Transferase (U/I), Creatine Phosphokinase (U/I)
Changes on anthropometry
waist circumference (cm), hip circumference (cm)
Changes on anthropometry
Weight (kg)
Changes on anthropometry
Body Mass Index (Kg/m2)
Changes on body composition
Fat mass (g), lean mass (g), visceral adipose tissue (g)
Changes on acne assessment
Global Acne Grading System (scale): each type of acne lesion is given a value depending on severity: no lesions = 0, comedones = 1, papules = 2, pustules = 3, and nodules = 4. Each of the location was graded separately on 0-4 scale, with the most severe lesion within that location determining the local score. The severity was then graded according to the global score which is the summation of all local scores. A score of 1-6 was considered mild; 7-18, moderate; 19- 26, severe; and 27-32, very severe. The maximum score was 32
Changes on acne assessment
Cardiff Acne Disability Index (scale): the Cardiff Acne Disability Index consists of five questions with a Likert scale, four response categories (0-3). The five questions relate to feeling of aggression, frustration, interference with social life, avoidance of public changing facilities and appearance of the skin-all over the last month-and an indication of how bad the acne was now. The CADI score was calculated by summing the score of each question resulting in a possible maximum of 15 and minimum of 0. CADI scores were graded as low (0-4), medium (5-9), and high (10-15)
Full Information
NCT ID
NCT04932070
First Posted
June 14, 2021
Last Updated
June 17, 2021
Sponsor
Azienda di Servizi alla Persona di Pavia
1. Study Identification
Unique Protocol Identification Number
NCT04932070
Brief Title
Berberine and Polycystic Ovary Syndrome
Official Title
Berberine is an Effective Insulin Sensitizer and Improves Homeostasis of Metabolic and Hormonal Disorders in Women With Polycystic Ovary Syndrome: a Novel Treatment Strategy for PCOS
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
September 5, 2020 (Actual)
Primary Completion Date
October 6, 2020 (Actual)
Study Completion Date
January 26, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Azienda di Servizi alla Persona di Pavia
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Polycystic Ovary Syndrome (PCOS) is the most frequent endocrine disease in female reproductive-age. Recently, increasing evidence has shown that natural plant-based products may play a role in PCOS management. Previous study in PCOS preclinical model and in humans demonstrated that berberine is an effective insulin sensitizer and improves homeostasis of metabolic, inflammatory and hormonal disorders. However, to date there is no clinical study that considers globally all the activities carried out by berberine in PCOS clinical features. Given this background, aim of this study was to evaluate in normal-overweight PCOS women with normal menses the berberine effectiveness on: insulin resistance by Homeostasis Model Assessment (HOMA); inflammation by C-Reactive Protein (CRP), TNF-alpha; lipid metabolism; sex hormone profile and symptoms correlated to hyperandrogenism, such as acne, by Global Acne Grading System (GAGS) and Cardiff Acne Disability Index (CADI); body composition by dual-energy X-ray absorptiometry. All these parameters were collected at baseline and 60 days after supplementation with a new bioavailable and safe berberine formulation. Finally, adverse effects were assessed by liver and kidney functions. To evaluate statistically significant pre- post-supplementation changes, fitted a linear mixed model for each investigated endpoint was performed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polycystic Ovary Syndrome, Berberine
Keywords
berberine, Polycystic Ovary Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Berberine
Arm Type
Experimental
Arm Description
2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
Intervention Type
Dietary Supplement
Intervention Name(s)
Berberine
Intervention Description
2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
Primary Outcome Measure Information:
Title
Changes on insulin resistance
Description
Homeostasis Model Assessment (pt), for evaluate insulin resistance if > 2.4
Time Frame
Changes from baseline insulin resistance at 8 weeks
Secondary Outcome Measure Information:
Title
Changes on inflammation
Description
C-Reactive Protein (mg/dl)
Time Frame
Changes from baseline inflammation at 8 weeks
Title
Changes on inflammation
Description
Tumor Necrosis Factor alpha (pg/ml)
Time Frame
Changes from baseline inflammation at 8 weeks
Title
Changes on lipid profile
Description
Total Cholesterol (mg/dl), High Density Lipoprotein Cholesterol (mg/dl), Low Density Lipoprotein Cholesterol (mg/dl), Very Low Density Lipoprotein (mg/dl),Triglycerides (mg/dl)
Time Frame
Changes from baseline lipid profile at 8 weeks
Title
Changes on Carbohydrate profile
Description
Glycemia (mg/dl)
Time Frame
Changes from baseline Carbohydrate profile at 8 weeks
Title
Changes on Carbohydrate profile
Description
Insulin (mcU/ml)
Time Frame
Changes from baseline Carbohydrate profile at 8 weeks
Title
Changes on Hormonal profile
Description
Sex Hormone Binding Globulin (nmol/l)
Time Frame
Changes from baseline Hormonal profile at 8 weeks
Title
Changes on Hormonal profile
Description
Testosterone (ng/ml)
Time Frame
Changes from baseline Hormonal profile at 8 weeks
Title
Changes on Hormonal profile
Description
Free Androgen Index (ratio)
Time Frame
Changes from baseline Hormonal profile at 8 weeks
Title
Changes on safety
Description
Aspartate aminotransferase (IU/l), alanine aminotransferase (IU/l)
Time Frame
Changes from baseline safety at 8 weeks
Title
Changes on safety
Description
Total bilirubin (mg/dl)
Time Frame
Changes from baseline safety at 8 weeks
Title
Changes on safety
Description
Gamma Glutamyl Transferase (U/I), Creatine Phosphokinase (U/I)
Time Frame
Changes from baseline safety at 8 weeks
Title
Changes on anthropometry
Description
waist circumference (cm), hip circumference (cm)
Time Frame
Changes from baseline anthropometry at 8 weeks
Title
Changes on anthropometry
Description
Weight (kg)
Time Frame
Changes from baseline anthropometry at 8 weeks
Title
Changes on anthropometry
Description
Body Mass Index (Kg/m2)
Time Frame
Changes from baseline anthropometry at 8 weeks
Title
Changes on body composition
Description
Fat mass (g), lean mass (g), visceral adipose tissue (g)
Time Frame
Changes from baseline body composition at 8 weeks
Title
Changes on acne assessment
Description
Global Acne Grading System (scale): each type of acne lesion is given a value depending on severity: no lesions = 0, comedones = 1, papules = 2, pustules = 3, and nodules = 4. Each of the location was graded separately on 0-4 scale, with the most severe lesion within that location determining the local score. The severity was then graded according to the global score which is the summation of all local scores. A score of 1-6 was considered mild; 7-18, moderate; 19- 26, severe; and 27-32, very severe. The maximum score was 32
Time Frame
Changes from baseline acne assessment at 8 weeks
Title
Changes on acne assessment
Description
Cardiff Acne Disability Index (scale): the Cardiff Acne Disability Index consists of five questions with a Likert scale, four response categories (0-3). The five questions relate to feeling of aggression, frustration, interference with social life, avoidance of public changing facilities and appearance of the skin-all over the last month-and an indication of how bad the acne was now. The CADI score was calculated by summing the score of each question resulting in a possible maximum of 15 and minimum of 0. CADI scores were graded as low (0-4), medium (5-9), and high (10-15)
Time Frame
Changes from baseline acne assessment at 8 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
normal and overweight women (Body Mass Index (BMI) 25-30 kg/m2)
newly detected Polycystic Ovary Syndrome
Exclusion Criteria:
any concomitant medication
presence of liver, renal and thyroid disease
smoking
drinking more than two standard alcoholic beverages/day (20 g of alcohol/day)
Facility Information:
Facility Name
Azienda di Servizi alla Persona
City
Pavia
ZIP/Postal Code
27100
Country
Italy
12. IPD Sharing Statement
Learn more about this trial
Berberine and Polycystic Ovary Syndrome
We'll reach out to this number within 24 hrs